Pictet Asset Management (Switzerland)’s Fate Therapeutics FATE Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$5.19M	Sell	1,090,260 -108,981	-9%	-$601K	0.01%	766
2023 Q1	$6.84M	Sell	1,199,241 -3,114	-0.3%	-$18.8K	0.01%	709
2022 Q4	$12.1M	Sell	1,202,355 -947,921	-44%	-$17.8M	0.02%	551
2022 Q3	$48.2M	Buy	2,150,276 +48,115	+2%	+$1.39M	0.07%	274
2022 Q2	$52.1M	Buy	2,102,161 +743,525	+55%	+$20.5M	0.07%	273
2022 Q1	$52.7M	Sell	1,358,636 -52,705	-4%	-$2.04M	0.06%	304
2021 Q4	$82.6M	Buy	1,411,341 +456,204	+48%	+$25.9M	0.08%	257
2021 Q3	$56.6M	Buy	+955,137	New	+$74.9M	0.06%	314

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s FATE Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Fate Therapeutics (FATE) stake by 9.1% in Q2 2023, selling an estimated $601K and leaving 1,090,260 shares worth $5.19M. The position accounts for 0.01% of the portfolio, ranked #766.

Pictet Asset Management (Switzerland) first reported a position in FATE in Q3 2021 and has held it in 8 quarters since. The position peaked at $82.6M in Q4 2021. 188 funds tracked by Wall St. Rank hold FATE as of Q2 2023.

Pictet Asset Management (Switzerland) held 1,090,260 shares of Fate Therapeutics worth $5.19M as of Q2 2023.
Pictet Asset Management (Switzerland) sold 108,981 Fate Therapeutics shares in Q2 2023, an estimated $601K.
Fate Therapeutics made up 0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #766 holding.
Pictet Asset Management (Switzerland) first reported a position in Fate Therapeutics in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s Fate Therapeutics position peaked at $82.6M in Q4 2021.
188 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.